Immunomedics Inc. (NASDAQ:IMMU)’s share price traded down 7.7% during trading on Monday . The company traded as low as $2.27 and last traded at $2.29, with a volume of 874,065 shares traded. The stock had previously closed at $2.48.

A number of equities analysts have commented on the stock. Wells Fargo & Co. restated a “buy” rating on shares of Immunomedics in a research note on Tuesday, May 24th. Jefferies Group restated a “buy” rating and issued a $5.00 target price on shares of Immunomedics in a research note on Monday, June 6th. Finally, Zacks Investment Research downgraded shares of Immunomedics from a “buy” rating to a “sell” rating in a research note on Tuesday, May 10th.

The firm’s market cap is $218.05 million. The stock’s 50-day moving average price is $3.25 and its 200-day moving average price is $2.81.

Immunomedics (NASDAQ:IMMU) last posted its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by $0.02. Analysts predict that Immunomedics Inc. will post ($0.57) EPS for the current year.

In other Immunomedics news, CEO Cynthia L. Goldenberg sold 371,990 shares of Immunomedics stock in a transaction dated Monday, June 13th. The shares were sold at an average price of $3.03, for a total transaction of $1,127,129.70. Following the transaction, the chief executive officer now directly owns 650,396 shares of the company’s stock, valued at $1,970,699.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman David M. Goldenberg sold 353,010 shares of Immunomedics stock in a transaction dated Wednesday, June 8th. The stock was sold at an average price of $3.88, for a total transaction of $1,369,678.80. Following the transaction, the chairman now directly owns 2,602,063 shares in the company, valued at $10,096,004.44. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Immunomedics stock. Marshall Wace LLP bought a new position in Immunomedics Inc. (NASDAQ:IMMU) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 857,062 shares of the biopharmaceutical company’s stock, valued at approximately $2,631,000. Marshall Wace LLP owned about 0.90% of Immunomedics as of its most recent SEC filing.

Immunomedics, Inc is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.